Asarina Pharma (Buy, TP: SEK44.00) - Approaching readout in PMDD
Asarina Pharma reported a Q4 operating loss of cSEK21m, slightly better than we expected. The ongoing phase IIb in PMDD is rapidly approaching readout, with a potential trigger at end-April. Clinical development in MM and Tourette’s continues to progress according to plan, with top-line results from the trial in MM expected in Q1 2021 and the initiation of the trial in Tourette’s expected by end-2020. We reiterate our BUY and SEK44 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.